Outcomes of Treatment With Dupilumab for Up to 5 Years in Adults With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
JAMA Dermatol 2024 Jul 10;[EPub Ahead of Print], LA Beck, R Bissonnette, M Deleuran, T Nakahara, R Galus, A Coleman, G Gherardi, J Xiao, R Dingman, C Xu, E Avetisova, A Dubost-Brama, A ShabbirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.